Issuer and reporting period
Important identity mismatch: The request names Neurogene Inc., but the supplied filing is Aquinox Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2018. This summary reflects the filing provided, not Neurogene.
Aquinox was a clinical-stage pharmaceutical company. On June 27, 2018, it announced that its Phase 3 Leadership 301 trial of rosiptor for interstitial cystitis/bladder pain syndrome (IC/BPS) failed its primary endpoint. It halted further rosiptor development and, as of the report, had no product candidates in clinical development or identified for clinical development.
Financial results and liquidity
Amounts below are in U.S. dollars; millions unless otherwise indicated.
| Metric | Three months ended June 30, 2018 | Six months ended June 30, 2018 | Comparable 2017 period |
|---|---|---|---|
| Revenue | $25.0 million | $25.0 million | None |
| Research and development | $18.0 million | $28.5 million | $10.5 million and $16.3 million |
| General and administrative | $4.3 million | $8.6 million | $3.5 million and $6.3 million |
| Total operating expenses | $22.3 million | $37.1 million | $14.0 million and $22.5 million |
| Net income (loss) | $2.9 million | $(11.7) million | $(13.8) million and $(22.1) million |
| Basic and diluted earnings (loss) per share | $0.12 | $(0.50) | $(0.59) and $(0.94) |
- The $25.0 million revenue was a non-refundable upfront payment under an Astellas license and collaboration agreement, not product-sales revenue. The filing says the payment was recognized in full after the rosiptor trial failure left Aquinox with no further performance obligations under the agreement.
- Cash and cash equivalents were $99.1 million at June 30, 2018; short-term investments were $3.0 million, for combined liquid resources of approximately $102.1 million. Working capital was $89.9 million and accumulated deficit was $210.2 million.
- Operating cash use was $6.4 million for the first half, versus $21.6 million a year earlier. Investing cash inflow of $52.9 million primarily reflected maturities of short-term investments; financing cash inflow was $0.6 million, primarily from option exercises.
- Total liabilities were $13.7 million, including $13.3 million of accounts payable and other liabilities. Other liabilities included $24,000 of capital lease obligations; the filing reports no material changes to contractual commitments.
- Gross margin is not presented; operating results include the one-time license payment and are not indicative of recurring product economics.
Changes, outlook, and material developments
- Second-quarter net income contrasted with losses in the comparable 2017 quarter, chiefly because of the Astellas upfront payment. First-half net loss narrowed from $22.1 million to $11.7 million despite higher operating expenses, also reflecting that revenue.
- R&D costs rose with Leadership 301 clinical activity; management expected R&D spending to decrease in the second half of 2018 after halting rosiptor development. Management also expected G&A expenses to decrease following restructuring.
- In July 2018, the board approved a restructuring that eliminated 30 positions, approximately 53% of the workforce, and closed the San Bruno office. Aquinox estimated approximately $2.5 million in restructuring charges, with most related cash payments expected in Q3 and the remainder in Q4 2018. Actual costs could differ and additional costs were possible.
- Management said existing capital resources were expected to fund operations for at least the next 12 months, but anticipated needing substantial future financing. The company warned financing might not be available on acceptable terms, or at all.
- Astellas received an exclusive, royalty-bearing rosiptor license in Japan and specified Asia-Pacific markets, excluding China and India. Future milestones and royalties were uncertain and might never be received; Astellas controls development and commercialization in the licensed territory.
Risks and items to verify
- Verify the issuer: the filing is for Aquinox Pharmaceuticals, Inc., not Neurogene Inc.
- Review the Leadership 301 trial results and the consequences of having no identified clinical-stage candidate or candidate in development.
- Assess the company’s post-restructuring strategy, pipeline plans, operating-cost base, and whether the stated 12-month liquidity outlook remains adequate.
- Confirm the estimated restructuring charge, timing of cash payments, and any additional workforce or facility-related costs.
- Distinguish the one-time $25.0 million license revenue from recurring revenue; assess the uncertain potential value of Astellas milestones and royalties.
- Consider capital-raising risk, potential dilution, and the filing’s stated dependence on future financing. The company reported foreign-currency exposure and no hedging, as well as reliance on third parties and significant intellectual-property and regulatory risks.
- The filing reports disclosure controls as effective at a reasonable assurance level and no material change in internal control over financial reporting during the quarter. It identifies no specific pending legal proceeding in the supplied text.